Adult cystic fibrosis service – publications list

Stressman F, Rogers B, Marsh P, Lilley A, **Daniels T**, **Carroll M**, Hoffamn L, Jones G, Allen C, Patel N, Forbes B, Tuck A, Bruce K. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? *Journal of Cystic Fibrosis* 2011; 10: 357-365

Stressman, F, Klem E, Lilley A, Donaldson S, **Daniels T**, **Carroll M**, Patel N, Forbes B, Boucher R, Wolfgang A, Bruce K. Analysis of the bacterial communities present in the lungs of Cystic Fibrosis patients from American and British centers. *Journal of Clinical Microbiology* 2011; 49: 281-291.

van der Gast CJ, Walker AW, Stressmann FA, Rogers GB, Scott P, **Daniels TWV**, Carroll MP, Parkhill J, Bruce KD Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities. *ISMEJ* 2010; 5: 780-791.

Rogers GB, Hoffman LR, Whitely M, **Daniels T**, **Carroll MP**, Bruce KD. (2010) Revealing the dynamics of polymicrobial infections: implications for antibiotic therapy. *Trends in Microbiology* 2010. 18; 357-364.

Daniels T. (2010) Letters: Upper and lower airway microbiology in cystic fibrosis, *Thorax*; **65**:278.

Rogers GB, Marsh P, Stressmann AF, Allen CE, **Daniels T**, **Carroll MP**, Bruce KD. (2010) The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples. *E. J. of Clin. Micro. & Inf. Dis*. 16 (11): 1656-1658.

Rogers GB, **Daniels T**, Tuck A, **Carroll MP**, Connett GJ, David JG, Bruce KD. (2009) Studying bacteria in respiratory specimens by using conventional and molecular microbiological approaches. *BMC Pulmonary Medicine* 9(1): 14

Rogers GB, Hoffman LR, Johnson MW, Mayer-Hamblett N, Schwarze J, **Carroll MP**, Bruce KD. Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset. Expert Rev Mol Diagn. 2011 Mar;11(2):197-206. Review.

Rogers GB, **Carroll MP**, Hoffman LR, Walker AW, Fine DA, Bruce KD. Comparing the microbiota of the cystic fibrosis lung and human gut. Gut Microbes. 2010 Mar;1(2):85-93.

Rogers GB, Stressmann FA, Walker AW, **Carroll MP**, Bruce KD. Lung infections in cystic fibrosis: deriving clinical insight from microbial complexity. Expert Rev Mol Diagn. 2010 Mar;10(2):187-96. Review.

Serisier DJ, **Carroll MP**, Shute JK, Young SA. Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum. Respir Res. 2009 Jul 6;10:63.

Spasenovski T, **Carroll MP**, Payne MS, Bruce KD. Molecular analysis of diversity within the genus Pseudomonas in the lungs of cystic fibrosis patients. Diagn Microbiol Infect Dis. 2009 Mar;63(3):261-7.

Shur J, Nevell TG, Ewen RJ, Price R, Smith A, Barbu E, Conway JH, **Carroll MP**, Shute JK, Smith JR. Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy. J Pharm Sci. 2008 Nov;97(11):4857-68.

Broughton-Head VJ, Shur J, **Carroll MP**, Smith JR, Shute JK. Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2007 Nov;293(5):L1240-9.

Rogers GB, **Carroll MP**, Serisier DJ, Hockey PM, Kehagia V, Jones GR, Bruce KD. Bacterial activity in cystic fibrosis lung infections. Respir Res. 2005 Jun 1;6:49.

Cawood AL**, Carroll MP**, Wootton SA, Calder PC. Is there a case for n-3 fatty acid supplementation in cystic fibrosis? Curr Opin Clin Nutr Metab Care. 2005 Mar;8(2):153-9. Review. PubMed PMID: 15716793.

Serisier DJ, Jones G, **Carroll M**. Eradication of pulmonary methicillin-resistant staphylococcus aureus (MRSA) in cystic fibrosis with linezolid. J Cyst Fibros. 2004 Mar;3(1):61.

Serisier DJ, Jones G, Tuck A, Connett G, **Carroll MP**. Clinical application of direct sputum sensitivity testing in a severe infective exacerbation of cystic fibrosis. Pediatr Pulmonol. 2003 Jun;35(6):463-6.